US-based clinical-stage biopharmaceutical company BeiGene has begun its Phase I clinical trial of BGB-290 in China to treat advanced solid tumours.
BGB-290 is a highly selective inhibitor of Poly (ADP-ribose) polymerase (PARP1) and PARP2 that is being developed as a monotherapy and in combination with other therapies to treat cancers such as ovarian cancer, prostate cancer, breast cancer, glioblastoma multiforme, small-cell lung cancer and gastric cancer.
It has exhibited favourable PARP1 and PARP2 selectivity in biochemical assays, as well as demonstrated improved specificity.
The Phase I trial is being conducted as an open-label, multi-centre dose escalation and expansion study of BGB-290 intended to determine safety, pharmacokinetics, and anti-tumour activity of BGB-290 in Chinese patients diagnosed with advanced solid tumours.
The trial will also determine the recommended dose for Phase II patients.
Professor Binghe Xu from The Chinese Academy of Medical Sciences Cancer Hospital is acting as the study's principal investigator.
Beigene founder and CEO John Oyler said: “We are pleased to announce the start of clinical development for BGB-290 in China, and we look forward to its rapid development following this Phase I study.
"BGB-290 entered clinical evaluation in Australia in July 2014, and proof of principle data were presented at the AACR-NCI-EORTC meeting in 2015.
"We look forward to developing BGB-290 for patients in China, where this class of agents is still not available."